Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Conditions
Interventions
Atezolizumab
Locations
21
United States
HonorHealth Research Institute - Pima Center
Scottsdale, Arizona, United States
The Angeles Clinic
Los Angeles, California, United States
Stanford Univ Medical Center; Dept Central Pharmacy
Stanford, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Moffitt Cancer Center
Tampa, Florida, United States
Uni of Chicago
Chicago, Illinois, United States
Start Date
June 21, 2011
Primary Completion Date
September 30, 2018
Completion Date
September 30, 2018
Last Updated
December 11, 2018
NCT01247597
NCT06898450
NCT06658951
NCT06625775
NCT05101070
NCT05719558
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions